Belzutifan · Welireg

Small molecule

Also known as MK-6482

Approvedregulatory verdict

Evidence outlook

Approved: Renal Cell Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
US
  • Pheochromocytoma or Paraganglioma WELIREG is indicated for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).
Product first approved 2021Outside this platform's coverageFDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Renal Cell Carcinoma
NCT07227402 · Merck Sharp & Dohme LLC
2025-11-26 – 2033-03-21 · Renal Cell Carcinoma
What this study did
NCT05239728 · Merck Sharp & Dohme LLC
2022-03-15 – 2029-09-28 · Carcinoma, Renal Cell
What this study did
NCT04586231 · Merck Sharp & Dohme LLC
2021-02-25 – 2027-02-11 · Carcinoma, Renal Cell
What this study did
NCT04195750 · Merck Sharp & Dohme LLC
2020-02-27 – 2026-10-14 · Carcinoma, Renal Cell
What this study did
Other / comorbidity
NCT07405164 · Merck Sharp & Dohme LLC
2026-03-23 – 2034-04-22 · Von Hippel-Lindau Disease, Malignant Neoplasms
What this study did
Phase 2 (17)
Renal Cell Carcinoma
NCT07593040 · Vall d'Hebron Institute of Oncology
2027-01 – 2031-06 · Renal Cell Carcinoma
What this study did
NCT07023432 · M.D. Anderson Cancer Center
2025-11-17 – 2030-04-14 · Active Surveillance, Clear Cell Renal Cell Carcinoma
What this study did
NCT07840001 · Peter MacCallum Cancer Centre, Australia
2026-12 – 2030-04 · Locally Advanced Clear Cell Renal Cell Carcinoma
What this study did
NCT07167329 · José Claudio Casali da Rocha
2024-01-01 – 2030-01-01 · Von Hippel Lindau, Von Hippel Lindau Disease, Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma, Hemangioblastoma (HB) of the Central Nervous System (CNS), PNET, Retinal Angiomatous Proliferation, Pheochromocytoma/Paraganglioma, Endolymphatic Sac Tumor
What this study did
NCT07187778 · M.D. Anderson Cancer Center
2025-12-19 – 2029-07-19 · Clear Cell Renal Cell Carcinoma
What this study did
NCT03401788 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2018-05-02 – 2027-04-29 · VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation, VHL-Associated Renal Cell Carcinoma, VHL-Associated Clear Cell Renal Cell Carcinoma
What this study did
NCT03634540 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2018-09-27 – 2027-02-26 · Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Cancer, Recurrent, Kidney
What this study did
NCT04489771 · Merck Sharp & Dohme LLC
2020-09-13 – 2026-08-25 · Carcinoma, Renal Cell
What this study did
Other / comorbidity
NCT07700758 · Merck Sharp & Dohme LLC
2026-10-13 – 2034-01-02 · Malignant Neoplasm
What this study did
NCT04924075 · Merck Sharp & Dohme LLC
2021-08-12 – 2032-11-18 · Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
What this study did
NCT07793942 · Merck Sharp & Dohme LLC
2026-10-21 – 2030-07-28 · Malignant Neoplam, Advanced Solid Tumors
What this study did
NCT06677190 · Dana-Farber Cancer Institute
2024-12-20 – 2030-06-30 · Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Vulvar Cancer, Gynecologic Cancer, Vaginal Cancer
What this study did
NCT06428396 · Merck Sharp & Dohme LLC
2024-11-27 – 2028-12-25 · Metastatic Breast Cancer
What this study did
NCT07895966 · University of Utah
2026-10-01 – 2028-09-30 · Erythrocytosis, Pulmonary Hypertension, Thrombosis
What this study did
NCT07680205 · Cambridge University Hospitals NHS Foundation Trust
2026-04-27 – 2027-12 · Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic, Pheochromocytoma/Paraganglioma, Pheochromocytoma
What this study did
NCT04976634 · Merck Sharp & Dohme LLC
2021-08-18 – 2027-03-22 · Neoplasm Malignant
What this study did
NCT05574712 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-01-01 – 2026-07 · Prostate Cancer
What this study did
Phase 1/2 (6)
Renal Cell Carcinoma
NCT05468697 · Merck Sharp & Dohme LLC
2022-08-10 – 2026-12-22 · Renal Cell Carcinoma
What this study did
NCT04626479 · Merck Sharp & Dohme LLC
2020-12-16 – 2026-08-10 · Carcinoma, Renal Cell
What this study did
NCT04626518 · Merck Sharp & Dohme LLC
2020-12-17 – 2026-07-23 · Carcinoma, Renal Cell
What this study did
Other / comorbidity
NCT07377526 · M.D. Anderson Cancer Center
2026-05-26 – 2030-03-01 · Pancreatic Cancer
What this study did
NCT02861573 · Merck Sharp & Dohme LLC
2016-11-17 – 2028-07-24 · Metastatic Castration-Resistant Prostate Cancer
What this study did
Phase 1 (11)
Renal Cell Carcinoma
NCT07179770 · NYU Langone Health
2025-09-15 – 2028-10-01 · Metastatic Clear Cell Renal Cell Carcinoma
What this study did
NCT06234605 · HiberCell, Inc.
2024-04-29 – 2027-11 · Renal Cell Carcinoma
What this study did
NCT02974738 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2016-12-07 – 2026-11-30 · Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, ccRCC, RCC, Clear Cell Adenocarcinoma, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Carcinoma, Clear Cell Adenocarcinoma, Glioblastoma, Glioblastoma, Adult, GBM, Glioblastoma Multiforme
What this study did
NCT04846920 · Merck Sharp & Dohme LLC
2021-06-14 – 2026-04-11 · Carcinoma, Renal Cell
What this study did
NCT04627064 · Dana-Farber Cancer Institute
2020-12-31 – 2024-08-04 · Clear Cell Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT07121959 · Merck Sharp & Dohme LLC
2025-08-18 – 2025-09-26 · Healthy
What this study did
NCT06903715 · Merck Sharp & Dohme LLC
2025-03-28 – 2025-05-27 · Healthy
What this study did
NCT04994522 · Merck Sharp & Dohme LLC
2022-07-12 – 2024-04-11 · End Stage Renal Disease, Renal Impairment
What this study did
NCT04995484 · Merck Sharp & Dohme LLC
2022-06-24 – 2024-01-03 · Moderate Hepatic Impairment
What this study did
NCT03445169 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2018-02-23 – 2018-05-26 · Healthy
What this study did
Phase 4 (1)
Other / comorbidity
NCT07907341 · Longfei Liu,MD
2026-04-01 – 2027-12-31 · Pheochromocytoma and Paraganglioma (PPGL)
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Renal Cell Carcinoma
NCT07489495 · Merck Sharp & Dohme LLC
2026-04-09 – 2030-11-27 · Carcinoma, Renal Cell
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Renal Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Belzutifan (Welireg): this drugApprovedSmall moleculeHIF-2alphanot yet gradedNo reviewed efficacy summary in this indication
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AvelumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
AxitinibApprovedSmall moleculeVEGFR1/2/3Partial signal
NCT02684006: Primaries in PD-L1-positive patients, avelumab + axitinib vs sunitinib: PFS (BICR) median 13.8 vs 7.2 months, hazard ratio 0.61 (95% CI 0.475 to 0.790), p=0.0001, met; OS median 43.2 vs 36.2 months, hazard ratio 0.86 (95% CI 0.701 to 1.057), p=0.1509, not significant (CT.gov posted results).
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signalNo reviewed efficacy summary in this indication
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01668784: Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Nivolumab 25 months | Everolimus 19.55 months (95% CI 17.64 to 23.06)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Pazopanib (Votrient)ApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signalFeatured results are non-efficacy only in this race
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02811861: Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Lenvatinib 18 mg Plus Everolimus 5 mg 14.7 months (95% CI 11.1 to 16.7) | Lenvatinib 20 mg Plus Pembrolizumab 200 mg 23.9 months (95% CI 20.8 to 27.7) | Sunitinib 50 mg 9.2 months (95% CI 6 to 11)
NCT04704219: Objective Response Rate (ORR) (Up to approximately 47 months): Pembrolizumab + Lenvatinib 50.6 Percentage of participants (95% CI 42.6 to 58.7)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Casdatifan
Phase 3(overall)
Small moleculeHIF-2alpha
not yet graded(overall)
No reviewed efficacy summary in this indication
DurvalumabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)Phase 3Small moleculeVEGFR1/2/3not yet gradedNo reviewed efficacy summary in this indication
Savolitinib (Orpathys)Phase 3Small moleculeMETnot yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
CiforadenantPhase 1/2Small moleculeadenosine A2Anot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Welireg (Belzutifan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
Phase 1Renal Cell CarcinomaRecruiting
Est. primary completion 2026-11 · NCT06234605 · CT.gov ↗
What to watch
December 2026 (1)
Phase 1/2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-22 · NCT05468697 · CT.gov ↗
What to watch
2027 (10)
February 2027 (1)
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-02-26 · NCT03634540 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Neoplasm MalignantActive not recruiting
Est. primary completion 2027-03-22 · NCT04976634 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic, Pheochromocytoma/Paraganglioma …Recruiting
Est. primary completion 2027-04 · NCT07680205 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-04-29 · NCT03401788 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-05-05 · NCT06428396 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-06-30 · NCT05030506 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-07-19 · NCT07187778 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-10-22 · NCT02861573 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Vulvar Cancer, Gynecologic Cancer, Vaginal CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06677190 · CT.gov ↗
What to watch
Phase 4Pheochromocytoma and Paraganglioma (PPGL)Recruiting
Est. primary completion 2027-12-31 · NCT07907341 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-01 · NCT07593040 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2028-04-14 · NCT07023432 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Malignant Neoplam, Advanced Solid TumorsRecruiting
Est. primary completion 2028-09-26 · NCT07793942 · CT.gov ↗
What to watch
Phase 2Erythrocytosis, Pulmonary Hypertension, ThrombosisNot yet recruiting
Est. primary completion 2028-09-30 · NCT07895966 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
Phase 2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2029-04 · NCT07840001 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2031-10-26 · NCT07049926 · CT.gov ↗
What to watch
2032 (2)
February 2032 (1)
Phase 3Renal Cell CarcinomaRecruiting
Est. primary completion 2032-02-27 · NCT07227402 · CT.gov ↗
What to watch
November 2032 (1)
Phase 2Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor …Recruiting
Est. primary completion 2032-11-18 · NCT04924075 · CT.gov ↗
What to watch
2034 (2)
January 2034 (1)
Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2034-01-02 · NCT07700758 · CT.gov ↗
What to watch
April 2034 (1)
Phase 3Von Hippel-Lindau Disease, Malignant NeoplasmsRecruiting
Est. primary completion 2034-04-22 · NCT07405164 · CT.gov ↗
What to watch

See the full readout calendar ↗